Boston Scientific (BSX) PT Raised to $120 at BTIG

Boston Scientific (BSX) PT Raised to $120 at Jefferies

Jefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $100.00) while maintaining a Buy rating.

The analyst comments "BSX reported 4Q24 sales of $4.56B, +19.5% organic, vs cons $4.42B and EPS of $0.70 +27% vs cons $0.66. BSX introduced '25 guidance... More

Boston Scientific (BSX) PT Raised to $122 at Citi

Citi analyst Joanna Wuensch raised the price target on Boston Scientific (NYSE: BSX) to $122.00 (from $107.00) while maintaining a Buy rating.

The analyst commment "BSX delivered another strong quarter meaningfully surpassing consensus, with four of the eight segments delivering double-digit growth, including Electrophysiology sales... More

Boston Scientific (BSX) PT Raised to $115 at BofA Securities

BofA Securities analyst Travis Steed raised the price target on Boston Scientific (NYSE: BSX) to $115.00 (from $110.00) while maintaining a Buy rating.

Boston Scientific reports above-consensus Q4 results, provides outlook

Investing.com -- Boston Scientific (NYSE: BSX) reported fiscal Q4 2024 results that surpassed analyst expectations.

The company's shares swung between gains and losses in premarket trading Wednesday.

The company reported earnings per share (EPS) of $0.70, topping analyst expectations of $0.66.... More

Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY25 EPS Guidance

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.70, $0.04 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.56 billion versus the consensus estimate of $4.41 billion.

GUIDANCE:

Boston Scientific sees FY2025 EPS of $2.80-$2.87, versus the consensus of... More

Boston Scientific (BSX) PT Raised to $115 at Piper Sandler

Piper Sandler analyst Matt O'Brien raised the price target on Boston Scientific (NYSE: BSX) to $115.00 (from $95.00) while maintaining a Overweight rating.... More